ZLAB
Zai Lab Limited
ZLAB lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
ZLAB Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Unavailable |
ZLAB's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
ZLAB PE Valuation
ZLAB has no meaningful PE right now: it lost money over the past year.
ZLAB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect ZLAB's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
ZLAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.19 | +$0.01 |
| Q2 2026 | -$0.18 | +$0.03 |
| Q1 2026 | -$0.17 | +$0.08 |
| Q4 2025 | -$0.16 | +$0.10 |
| Q3 2025 | -$0.20 | +$0.07 |
| Q2 2025 | -$0.21 | +$0.09 |
| Q1 2025 | -$0.25 | +$0.10 |
| Q4 2024 | -$0.26 | +$0.09 |
ZLAB is still losing money, but far less than before: $0.19 per share over the past year, against $0.46 at its worst in late 2022.
ZLAB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $108.2M | -6.8% |
| Q2 2026 | $106.3M | -3.3% |
| Q1 2026 | $99.6M | -6.5% |
| Q4 2025 | $127.6M | +17% |
| Q3 2025 | $116.1M | +14% |
| Q2 2025 | $110M | +9.4% |
| Q1 2025 | $106.5M | +22% |
| Q4 2024 | $109.1M | +66% |
ZLAB's revenue has held roughly level: $108M last quarter, down 6.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -58% | -16 points |
| Q2 2026 | -72% | -22 points |
| Q1 2026 | -70% | -17 points |
| Q4 2025 | -54% | +7.9 points |
| Q3 2025 | -42% | +24 points |
| Q2 2025 | -50% | +26 points |
| Q1 2025 | -53% | +28 points |
| Q4 2024 | -62% | +126 points |
ZLAB's operating margin was −58% last quarter, down 16 points from the same quarter a year ago.
ZLAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$58.8M | -$23.8M |
| Q2 2026 | -$64.7M | -$30.8M |
| Q1 2026 | -$13.1M | +$50.1M |
| Q4 2025 | -$26.7M | +$31.7M |
| Q3 2025 | -$35M | -$6.9M |
| Q2 2025 | -$33.9M | +$9M |
| Q1 2025 | -$63.2M | +$27.8M |
| Q4 2024 | -$58.4M | -$43.2M |
ZLAB has burned cash in almost every quarter: −$163M over the past year, against −$191M the year before.
ZLAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +6.4M shares |
| 1 year | +1.9% | +21.3M shares |
| 3 years | +16% | +155M shares |
ZLAB has 1.1B diluted shares, up 1.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
ZLAB Net Leverage
ZLAB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ZLAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.3 | Neutral |
| Stochastic | 60.8 | Neutral |
ZLAB's weekly RSI is 58 (neutral) and its Stochastic is 61 (neutral).
ZLAB PE vs Healthcare Sector
ZLAB has no meaningful PE right now: it lost money over the past year.
ZLAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $24.4 | 6.8% above |
| 20 week MA | $23.5 | 11% above |
| 50 week MA | $20.8 | 25% above |
| 100 week MA | $25.9 | 0.5% above |
| 200 week MA | $25.8 | 0.8% above |
ZLAB is in an uptrend: it's above all five of its weekly moving averages, and 0.8% above its 200-week average.
ZLAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.3 | $133.8 | +232% |
| 2021 | $133.8 | $65.8 | -51% |
| 2022 | $65.8 | $30.8 | -53% |
| 2023 | $30.8 | $27.3 | -11% |
| 2024 | $27.3 | $26.6 | -2.6% |
| 2025 | $26.6 | $18.3 | -31% |
| 2026 YTD | $18.3 | $26.0 | +42% |
ZLAB has finished five years in a row lower, and it's up 42% so far in 2026.